Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.4% – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was down 2.4% during mid-day trading on Tuesday . The stock traded as low as $7.50 and last traded at $7.76. Approximately 8,984,496 shares changed hands during trading, a decline of 44% from the average daily volume of 15,902,586 shares. The stock had previously closed at $7.95.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Down 4.4 %

The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market capitalization of $2.97 billion, a P/E ratio of -4.97 and a beta of 0.85. The firm’s fifty day moving average price is $6.89 and its 200-day moving average price is $7.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period in the previous year, the business posted ($0.43) earnings per share. The business’s revenue for the quarter was up 147.6% compared to the same quarter last year. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Activity

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total transaction of $76,351.49. Following the sale, the director now owns 7,089,007 shares in the company, valued at approximately $47,283,676.69. The trade was a 0.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $6.31, for a total transaction of $37,860.00. Following the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at $3,288,380.78. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,341 shares of company stock worth $393,490. Corporate insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Recursion Pharmaceuticals by 17.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after acquiring an additional 288,926 shares during the last quarter. FMR LLC increased its position in Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after purchasing an additional 170,810 shares during the last quarter. State Street Corp raised its stake in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after buying an additional 656,003 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new position in Recursion Pharmaceuticals in the second quarter worth approximately $5,769,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.